Human natural killer cells: Origin, receptors, function, and clinical applications

Lorenzo Moretta, Elisa Montaldo, Paola Vacca, Genny Del Zotto, Francesca Moretta, Pietro Merli, Franco Locatelli, Maria Cristina Mingari

Research output: Contribution to journalArticle

Abstract

Natural killer (NK) cells are important effectors playing a relevant role in innate immunity, primarily in tumor surveillance and in defenses against viruses. Human NK cells recognize HLA class I molecules through surface receptors (KIR and NKG2A) that inhibit NK cell function and kill target cells that have lost (or underexpress) HLA class I molecules as it occurs in tumors or virus-infected cells. NK cell activation is mediated by an array of activating receptors and co-receptors that recognize ligands expressed primarily on tumors or virus-infected cells. In vivo anti-tumor NK cell activity may be suppressed by tumor or tumor-associated cells. Alloreactive NK cells (i.e. those that are not inhibited by the HLA class I alleles of the patient) derived from HSC of haploidentical donors play a major role in the cure of high-risk leukemia, by killing leukemia blasts and patient's DC, thus preventing tumor relapses and graft-versus-host disease. The expression of the HLA-C2-specific activating KIR2DS1 may also contribute to NK alloreactivity in patients expressing C2 alleles. A clear correlation has been proven between the size of the alloreactive NK cell population and the clinical outcome. Recently, haplo-HSCT has been further improved with the direct infusion, together with HSC, of donor-derived, mature alloreactive NK cells and TCRγδ + T cells-both contributing to a prompt anti-leukemia effect together with an efficient defense against pathogens during the 6-to 8-week interval required for the generation of alloreactive NK cells from HSC.

Original languageEnglish
Pages (from-to)253-264
Number of pages12
JournalInternational Archives of Allergy and Immunology
Volume164
Issue number4
DOIs
Publication statusPublished - Nov 7 2014

Fingerprint

Natural Killer Cell Receptors
Natural Killer Cells
Oncogenic Viruses
Leukemia
Neoplasms
NK Cell Lectin-Like Receptor Subfamily C
Alleles
Tissue Donors
KIR Receptors
Graft vs Host Disease
Innate Immunity
Ligands
Viruses
T-Lymphocytes
Recurrence

Keywords

  • Activating NK receptors
  • Haploidentical hematopoietic stem cell transplantation
  • Killer Ig-like receptors
  • Natural killer cells
  • NK-tumor cell interactions

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Human natural killer cells : Origin, receptors, function, and clinical applications. / Moretta, Lorenzo; Montaldo, Elisa; Vacca, Paola; Del Zotto, Genny; Moretta, Francesca; Merli, Pietro; Locatelli, Franco; Mingari, Maria Cristina.

In: International Archives of Allergy and Immunology, Vol. 164, No. 4, 07.11.2014, p. 253-264.

Research output: Contribution to journalArticle

@article{6c1b14c5d4ed4d4d81e0cb067f3826dc,
title = "Human natural killer cells: Origin, receptors, function, and clinical applications",
abstract = "Natural killer (NK) cells are important effectors playing a relevant role in innate immunity, primarily in tumor surveillance and in defenses against viruses. Human NK cells recognize HLA class I molecules through surface receptors (KIR and NKG2A) that inhibit NK cell function and kill target cells that have lost (or underexpress) HLA class I molecules as it occurs in tumors or virus-infected cells. NK cell activation is mediated by an array of activating receptors and co-receptors that recognize ligands expressed primarily on tumors or virus-infected cells. In vivo anti-tumor NK cell activity may be suppressed by tumor or tumor-associated cells. Alloreactive NK cells (i.e. those that are not inhibited by the HLA class I alleles of the patient) derived from HSC of haploidentical donors play a major role in the cure of high-risk leukemia, by killing leukemia blasts and patient's DC, thus preventing tumor relapses and graft-versus-host disease. The expression of the HLA-C2-specific activating KIR2DS1 may also contribute to NK alloreactivity in patients expressing C2 alleles. A clear correlation has been proven between the size of the alloreactive NK cell population and the clinical outcome. Recently, haplo-HSCT has been further improved with the direct infusion, together with HSC, of donor-derived, mature alloreactive NK cells and TCRγδ + T cells-both contributing to a prompt anti-leukemia effect together with an efficient defense against pathogens during the 6-to 8-week interval required for the generation of alloreactive NK cells from HSC.",
keywords = "Activating NK receptors, Haploidentical hematopoietic stem cell transplantation, Killer Ig-like receptors, Natural killer cells, NK-tumor cell interactions",
author = "Lorenzo Moretta and Elisa Montaldo and Paola Vacca and {Del Zotto}, Genny and Francesca Moretta and Pietro Merli and Franco Locatelli and Mingari, {Maria Cristina}",
year = "2014",
month = "11",
day = "7",
doi = "10.1159/000365632",
language = "English",
volume = "164",
pages = "253--264",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Human natural killer cells

T2 - Origin, receptors, function, and clinical applications

AU - Moretta, Lorenzo

AU - Montaldo, Elisa

AU - Vacca, Paola

AU - Del Zotto, Genny

AU - Moretta, Francesca

AU - Merli, Pietro

AU - Locatelli, Franco

AU - Mingari, Maria Cristina

PY - 2014/11/7

Y1 - 2014/11/7

N2 - Natural killer (NK) cells are important effectors playing a relevant role in innate immunity, primarily in tumor surveillance and in defenses against viruses. Human NK cells recognize HLA class I molecules through surface receptors (KIR and NKG2A) that inhibit NK cell function and kill target cells that have lost (or underexpress) HLA class I molecules as it occurs in tumors or virus-infected cells. NK cell activation is mediated by an array of activating receptors and co-receptors that recognize ligands expressed primarily on tumors or virus-infected cells. In vivo anti-tumor NK cell activity may be suppressed by tumor or tumor-associated cells. Alloreactive NK cells (i.e. those that are not inhibited by the HLA class I alleles of the patient) derived from HSC of haploidentical donors play a major role in the cure of high-risk leukemia, by killing leukemia blasts and patient's DC, thus preventing tumor relapses and graft-versus-host disease. The expression of the HLA-C2-specific activating KIR2DS1 may also contribute to NK alloreactivity in patients expressing C2 alleles. A clear correlation has been proven between the size of the alloreactive NK cell population and the clinical outcome. Recently, haplo-HSCT has been further improved with the direct infusion, together with HSC, of donor-derived, mature alloreactive NK cells and TCRγδ + T cells-both contributing to a prompt anti-leukemia effect together with an efficient defense against pathogens during the 6-to 8-week interval required for the generation of alloreactive NK cells from HSC.

AB - Natural killer (NK) cells are important effectors playing a relevant role in innate immunity, primarily in tumor surveillance and in defenses against viruses. Human NK cells recognize HLA class I molecules through surface receptors (KIR and NKG2A) that inhibit NK cell function and kill target cells that have lost (or underexpress) HLA class I molecules as it occurs in tumors or virus-infected cells. NK cell activation is mediated by an array of activating receptors and co-receptors that recognize ligands expressed primarily on tumors or virus-infected cells. In vivo anti-tumor NK cell activity may be suppressed by tumor or tumor-associated cells. Alloreactive NK cells (i.e. those that are not inhibited by the HLA class I alleles of the patient) derived from HSC of haploidentical donors play a major role in the cure of high-risk leukemia, by killing leukemia blasts and patient's DC, thus preventing tumor relapses and graft-versus-host disease. The expression of the HLA-C2-specific activating KIR2DS1 may also contribute to NK alloreactivity in patients expressing C2 alleles. A clear correlation has been proven between the size of the alloreactive NK cell population and the clinical outcome. Recently, haplo-HSCT has been further improved with the direct infusion, together with HSC, of donor-derived, mature alloreactive NK cells and TCRγδ + T cells-both contributing to a prompt anti-leukemia effect together with an efficient defense against pathogens during the 6-to 8-week interval required for the generation of alloreactive NK cells from HSC.

KW - Activating NK receptors

KW - Haploidentical hematopoietic stem cell transplantation

KW - Killer Ig-like receptors

KW - Natural killer cells

KW - NK-tumor cell interactions

UR - http://www.scopus.com/inward/record.url?scp=84908566276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908566276&partnerID=8YFLogxK

U2 - 10.1159/000365632

DO - 10.1159/000365632

M3 - Article

C2 - 25323661

AN - SCOPUS:84908566276

VL - 164

SP - 253

EP - 264

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 4

ER -